CSIMarket
 


Opiant Pharmaceuticals Inc   (OPNT)
Other Ticker:  
 

Cumulative Opiant Pharmaceuticals Inc 's Working Capital Ratio for Trailing Twelve Months Period

OPNT's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

OPNT Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Growth -13.34 % -13.65 % 10.39 % 6.63 % 9.72 %
Y / Y Current Assets Growth -43.21 % -21.08 % 5.45 % 17.02 % 67.27 %
Working Capital Ratio for Trailing Twelve Months Period 8.59 9.39 9.59 9.71 9.48
Total Ranking # 567 # 630 # 641 # 644 # 514
Seq. Current Liabilities Growth 27.56 % -26.41 % -0.85 % -6.89 % 27.11 %
Seq. Current Assets Growth -19.28 % -19.27 % -14.46 % 1.89 % 12.16 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2022
On the trailing twelve months basis Despite year on year decrease in Opiant Pharmaceuticals Inc 's average Current Liabilities to $6 millions, Working Capital Ratio for Trailing Twelve Months Period to 8.59 below company average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 273 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Opiant Pharmaceuticals Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about OPNT
Working Capital Ratio OPNT in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 274
Sector # 472
S&P 500 # 798


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
9.71 5.84 2.39
(Dec 31 2021)   (Oct 31 2017)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Astria Therapeutics inc   23.42 
Agios Pharmaceuticals Inc   23.32 
Eliem Therapeutics Inc   23.23 
Lixte Biotechnology Holdings Inc   23.06 
Oramed Pharmaceuticals Inc   22.36 
Rani Therapeutics Holdings Inc   22.06 
Arena Pharmaceuticals Inc   21.88 
Kinnate Biopharma Inc   21.17 
Generation Bio Co   21.16 
Kalvista Pharmaceuticals Inc   20.91 
Pardes Biosciences Inc   20.85 
Rallybio Corporation  20.84 
Nkarta Inc   20.57 
Biomea Fusion Inc   20.50 
Belite Bio Inc  20.35 
Anixa Biosciences Inc   20.35 
Seres Therapeutics Inc   19.94 
Io Biotech Inc   19.90 
Minerva Neurosciences Inc   19.51 
Keros Therapeutics Inc   19.41 
Kronos Bio Inc   19.33 
Genprex Inc   19.30 
Caladrius Biosciences Inc   19.11 
Sage Therapeutics Inc   19.11 
Lantern Pharma Inc   19.00 
Reviva Pharmaceuticals Holdings Inc   18.86 
Reneo Pharmaceuticals Inc   18.77 
Forte Biosciences Inc   18.54 
Zevra Therapeutics Inc   18.51 
Alx Oncology Holdings Inc  18.49 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com